Literature DB >> 9894365

A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin.

S Hern1, K Harman, B S Bhogal, M M Black.   

Abstract

Pemphigoid gestationis is an autoimmune bullous eruption specific to pregnancy. It usually presents in the second or third trimester and is characterized by postpartum exacerbations of the disease. Most cases resolve within a few months of delivery, but the disease may be more persistent, developing characteristics of bullous pemphigoid which can be difficult to treat. We now report a patient with severe pemphigoid gestationis, in whom the disease has persisted for 1.5 years postpartum and who developed features more typical of bullous pemphigoid. We discuss this phenomenon and the management of such cases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9894365     DOI: 10.1046/j.1365-2230.1998.00342.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  5 in total

1.  High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders.

Authors:  S Jolles
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

2.  A resistant case of pemphigus gestationis successfully treated with cyclosporine.

Authors:  Özhan Özdemir; Cemal Resat Atalay; Vusala Asgarova; Bunyamin Ugur Ilgin
Journal:  Interv Med Appl Sci       Date:  2016-03

3.  Pemphigoid gestationis.

Authors:  Céline M J G Lardenoije; Marije van de Water; Helena J M M Mertens; Ed T C M Gondrie
Journal:  BMJ Case Rep       Date:  2011-02-08

Review 4.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 5.  Gestational pemphigoid.

Authors:  Laura Huilaja; Kaarin Mäkikallio; Kaisa Tasanen
Journal:  Orphanet J Rare Dis       Date:  2014-09-02       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.